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 ABSTRACT 
Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum biomarker for chronic hepatitis 
that was discovered by proteomics analysis. FIC5.9 is derived from the C-terminal region of fibrinogen 
alpha chain. The serum levels of FIC5.9 decrease in chronic hepatitis. Previous studies have suggested that 
FIC5.9 cannot be detected in the systemic circulation and is only synthesized during blood clotting. 
However, the mechanism of FIC5.9 synthesis is unclear. Based on our previous work, I formulated a 
hypothesis that FIC5.9 is synthesized by enzymes that are activated post-blood collection and may be 
coagulation and fibrinolysis factors. In this study, I analyzed the mechanisms of FIC5.9 synthesis in 
healthy blood. Our analysis showed that thrombin acts as an initiator for FIC5.9 synthesis, and that plasmin 
and neutrophil elastase cleaves FIC5.9 from fibrinogen. The results indicate that FIC5.9 reflects and 
amplifies minute changes in coagulation and fibrinolysis factors associated with pathological conditions. 
 
 INTRODUCTION 
Many biomarkers have been discovered by proteomics analysis, but fewer have been developed for 
clinical use (1, 2). Most reported biomarkers involve posttranslational modification or degradation, and it 
may be unclear why the level of the biomarker changes in disease. Thus, there is a need to establish links 
between the synthetic mechanism of the biomarker and disease conditions for practical use in clinical 
diagnosis (3). 
Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum marker for chronic hepatitis that 
was discovered in samples from cases of alcoholic liver disease using SELDI-TOF MS (4). FIC5.9 is 
derived from the C-terminal region of fibrinogen alpha chain and has a molecular weight is 5890 Da. The 
level of FIC5.9 is high in healthy people and decreases with onset of hepatitis (5-7). I developed an ELISA 
system for FIC5.9 and evaluated the clinical utility of FIC5.9 in various kinds of chronic hepatitis (8). This 
analysis showed that the serum level of FIC5.9 is significantly decreased in the early stage of liver fibrosis 
and that this is a strong indicator for liver fibrosis. The results also indicated that FIC5.9 is not synthesized 
in the circulation, but in the blood collection tube during the process of blood coagulation. That is, FIC5.9 
is synthesized from blood collected from healthy subjects and in vitro products in the collection tube. Since 
our initial identification of FIC5.9, the same peptide or an unidentified peptide with the same nominal 
mass has been reported to be of diagnostic value in a variety of pathological conditions including cancers 
and inflammatory disorders (8-14). However, the mechanism of FIC5.9 production is unknown.  
Based on these results, I formulated a hypothesis that FIC5.9 is synthesized from fibrinogen or fibrin by 
an enzyme that is activated post-blood collection, with this synthesis involving coagulation and fibrinolysis 
factors. The FIC5.9 sequence includes amino acids 576-629 of the fibrinogen alpha chain (Fig. 1) and 
FIC5.9 appears to be synthesized by cleavage at RGK/SSS (N-terminal region) and RPV/RGI (C-terminal 
region) (4). Trypsin cleaves to the carboxyl side of lysine, but plasmin and thrombin are the major enzymes 
that work with fibrinogen or fibrin (15). There are fewer reports of enzymes in blood that cleave to the 
carboxyl side of valine, but neutrophil elastase is one such example (16). In this study, as a first step 
toward understanding the mechanisms of FIC5.9 alterations in various pathologies, I tested the hypothesis 
 that FIC5.9 is synthesized by these enzymes in apparently healthy subjects. 
 
EXPERIMENTAL PROCEDURES 
FIC5.9 synthesis during blood clotting 
To confirm the conclusion of our previous study (8) regarding the roles of coagulation factors in 
synthesis of FIC5.9, the coagulation cascade was reactivated by adding Thrombocheck APTT-SLA 
(Sysmex Corp., Hyogo, Japan) to coagulation-deficient plasma (factor II, V, VII, VIII, IX, X, XI, XII; 
Sysmex). Control plasma was collected with Insepack II (sodium citrate type, Sekisui Medical Co., Tokyo, 
Japan). After a 1-hour incubation at 25°C, samples were centrifuged at 3000 rpm for 20 min. The 
supernatant was purified with C18/WCX cartridges (4). FIC5.9 levels in samples were measured by 
MALDI-TOF MS on a Bruker AUTOFlex® mass spectrometer, using stable isotope-labeled FIC5.9 as an 
internal standard (4). 
 
In vitro degradation of purified fibrinogen 
Purified fibrinogen (Wako Pure Chemical Industries, Tokyo, Japan; 70 µg) in PBS buffer was incubated 
with thrombin (Wako; final conc. 2 U/mL), plasmin (Wako; 1 U/mL) or neutrophil elastase (Sigma-Aldrich, 
St. Louis, MO, USA; 1 U/mL) for 2 h at 25°C. The reaction was stopped by adding EDTA (pH 8.0, 10 
mM) and aprotinin (Wako; 1 U/mL). 
 
LC-MS/MS analysis of degradation products of fibrinogen 
StageTips C18 (Thermo Fisher Scientific, Waltham, MA, USA) was used for desalting the degradation 
products of fibrinogen (17). Obtained peptides were identified by LC/MS/MS analysis (18). 
 
Analysis and time course of FIC5.9 synthesis in blood collection tubes 
Blood collection tubes (Insepack II, Sekisui Medical Co.) with added thrombin (Wako; 20 U/mL (19)), 
hirudin (Thermo Fisher; 1 U/mL (19)), plasmin (Wako; 0.8 U/mL (20)), tranexamic acid (Wako; 10 mM 
 (20)), sivelestat sodium (Cosmo Bio Co.; Tokyo Japan; 80 µM (21)) or the same volume of saline were 
used to collect blood samples from six healthy volunteers. The collected blood was clotted for 0, 5, 30, 60, 
90 min at 25°C. After blood clotting, serum was obtained by centrifugation at 3000 rpm for 10 min at 4°C. 
The level of FIC5.9 was measured using a FIC5.9 ELISA kit (6). All volunteers gave informed consent and 
the study was approved by the ethics committee of our institute. 
 
Statistical analysis 
Statistical analysis was performed by Mann-Whitney U-test with SPSS software, version 18.0 (SPSS 
Inc., Chicago, IL, USA). A P value less than 0.05 was considered significant. 
 
RESULTS 
LC-MS/MS analysis of degradation products of fibrinogen in vitro 
FIC5.9 is synthesized in the blood collection tube during blood clotting (8). Confirmatory experiments 
in the current study showed that a deficiency of factors II, V, VIII and X decreased the synthesis of FIC5.9 
(Fig. 2), and that factor II (thrombin) had a particularly marked effect on the synthesis of FIC5.9 (8). To 
determine the coagulation and fibrinolysis factors that produce FIC5.9, I narrowed down the candidate 
enzymes based on these results, well-known enzymes that catalyze fibrinogen, and enzymes that cleave at 
sites consistent with synthesis of FIC5.9. Information on enzyme cleavage sites was obtained from the 
Peptidase Database (MEROPS: http://merops.sanger.ac.uk). Thrombin, plasmin and neutrophil elastase 
were selected. Next, the sequences of degradation products obtained from the reaction of fibrinogen and 
these enzymes were analyzed by LC-MS/MS (Fig. 3, and Table). The results suggested that the N-terminal 
region of FIC5.9 (RGK/SSS) is cleaved by thrombin or plasmin, and that the C-terminal region of FIC5.9 
(RPV/RGI) is cleaved by neutrophil elastase. 
 
Analysis and time course of FIC5.9 synthesis in blood collection tubes 
To determine if thrombin, plasmin and neutrophil elastase can synthesize FIC5.9 in blood, I analyzed 
 the synthesis and time course of FIC5.9 in blood collection tubes containing thrombin, hirudin (a thrombin 
inhibitor), plasmin, tranexamic acid (a plasmin inhibitor), or sivelestat sodium (a neutrophil elastase 
inhibitor). I first examined FIC5.9 synthesis and clotting time in plain and silica-coated tubes by 
measurement of FIC5.9 in serum after 0, 5, 30, 60, 90 min of clotting and centrifugation. The rate of 
synthesis of FIC5.9 in a silica-coated tube was significantly faster than that in a plain tube (Fig. 4), but the 
final FIC5.9 levels did not differ significantly between these tubes. All further analyses (including clinical 
evaluation of FIC5.9 as a biomarker in chronic hepatitis) were performed in silica-coated tubes 
In all experiments, FIC5.9 was detected at 0 min of clotting. However, there is a time lag between 
blood collection and dispensing into the collection tube. The rate of synthesis of FIC5.9 in tubes with 
added thrombin was significantly faster than that in silica-coated tubes. Synthesis of FIC5.9 reached a 
plateau after 30 min clotting and the same amount of FIC5.9 was synthesized in the silica-coated and plain 
tubes (Fig. 5A). Addition of hirudin (thrombin inhibitor) significantly delayed the synthesis of FIC5.9, but 
prolonged synthesis to after 90 minutes of clotting. With plasmin, the synthesis rate and total amount of 
FIC5.9 were significantly increased, and addition of tranexamic (plasmin inhibitor) markedly decreased 
the synthesis of FIC5.9 (Fig. 5B). Addition of sivelestat sodium (neutrophil elastase inhibitor) completely 
inhibited synthesis of FIC5.9 (Fig. 5C). These results suggest that plasmin and neutrophil elastase 
synthesize FIC5.9 directly. 
 
DISCUSSION 
In this study, I formulated a hypothesis that FIC5.9 is synthesized from fibrinogen by coagulation and 
fibrinolysis factors. This hypothesis was tested by digesting purified fibrinogen with thrombin, plasmin 
and neutrophil elastase in vitro and analysis of fragments of fibrinogen by LC-MS/MS. The results showed 
that the N-terminal end of FIC5.9 (RGK/SSS) is cleaved by thrombin or plasmin, and the C-terminal end 
of FIC5.9 (RPV/RGI) is cleaved by neutrophil elastase (Fig. 3) in vitro. To confirm that these enzymes can 
synthesize FIC5.9 during blood coagulation, the synthesis and time course of FIC5.9 were analyzed in 
blood collection tubes spiked with thrombin, plasmin, neutrophil elastase, or inhibitors of these enzymes. 
 Addition of thrombin or plasmin accelerated the synthesis of FIC5.9, and inhibition of all three enzymes 
significantly decreased the synthesis of FIC5.9 (Fig. 5). These results show that the mechanism of FIC5.9 
synthesis in healthy people is strongly related to coagulation and fibrinolysis factors. 
Both thrombin and plasmin can cleave the N-terminal end of FIC5.9 (RGK/SSS), but addition of 
thrombin into blood collection tube resulted in only acceleration of FIC5.9 synthesis and no significant 
difference did not alter the final amount of FIC5.9 synthesized, whereas addition of plasmin markedly 
increased the final amount of FIC5.9. The different results for thrombin or plasmin are of interest. 
Inhibition of thrombin (adding hirudin) delayed the synthesis of FIC5.9, but there was no significant 
difference at 90 minutes clotting. These results indicate that thrombin is essential for initiation of FIC5.9 
synthesis, but is less important with regard to the amount of FIC5.9 produced. Plasmin is the significant 
enzyme that cleaves the N-terminal region of FIC5.9 and affects the amount of FIC5.9. In nature, 
activation of plasminogen to plasmin occurs after activation of coagulation factors (22, 23). These reports 
also support the role of thrombin as the initiator of FIC5.9 synthesis. 
Our results suggests why FIC5.9 is a marker of alcoholic liver disease and liver fibrosis (4)-(8). 
Neutrophil elastase cleaves the C-terminal site of FIC5.9, but only a few reports indicate that the level of 
neutrophil elastase (or the neutrophil count) changes in the early stage of chronic hepatitis (24, 25). 
Therefore, the C-terminal site of FIC5.9 is likely to be cleaved at a similar level in healthy people and 
patients with chronic hepatitis. However, an extreme increase or decrease in neutrophils might affect the 
synthesis of FIC5.9. A spike test of neutrophil elastase into the collection tube could not be performed, but 
the results of LC-MS/MS indicated that neutrophil elastase can cleave the C-terminal region of FIC5.9. 
This requires confirmation in a further study. 
Thrombin (the initiator of FIC5.9 synthesis) and plasmin (which significantly cleaves the N-terminal 
site of FIC5.9) are molecular markers of liver disease, partly because both enzymes are secreted from liver 
(26-30). Our study suggests that the decrease in FIC5.9 levels in chronic hepatitis is caused by dysfunction 
of coagulation and fibrinolysis factors, since some levels of these factors change in chronic liver disease 
(31, 32). The marked change in the level of FIC5.9 in the early stage of liver fibrosis (8) might occur 
 because changes in all of these factors affect FIC5.9 synthesis synergistically. The presence of other factors 
related to FIC5.9 synthesis also requires consideration. Recently, Marfa et al. reported that TGF-b reduces 
the expression level of fibrinogen alpha chain mRNA (7). The level of TGF-b is closely related to liver 
fibrosis and hepatitis (33, 34). Plasma fibrinogen is also a marker for chronic liver disease (35). These 
reports are important for investigation of the mechanisms of FIC5.9 synthesis. 
Measurement of degradation products in blood circulation is commonly used in clinical tests (36, 37). 
Most coagulation and fibrinolysis factors are unstable for measurement of activity (38)-(40), as 
exemplified by the activated partial thromboplastin time (APTT) and the prothrombin time (PT). FIC5.9 is 
also a degradation product from fibrinogen alpha chain that is synthesized by coagulation and fibrinolysis 
factors, and reflects a minute change in these factors. Thrombin, plasmin and neutrophil elastase are 
involved in the synthetic mechanism of FIC5.9 in clotting of normal blood. This provides the basis for 
understanding the decrease in FIC 5.9 in clotting of blood from patients with chronic hepatitis. Further 
analysis may show similar effects in blood from patients with other diseases. 
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 FIGURE LEGENDS 
FIGURE 1. Sequences of fibrinogen alpha chain and FIC5.9. The mature alpha chain is indicated by a grey 
shadow. The FIC5.9 sequence (amino acids 576-629) is underlined. 
 
FIGURE 2. Analysis of FIC5.9 synthesis in coagulation factor-deficient plasma. (A) Mass spectrum of 
coagulation-depleted plasma reactivated using an APTT reagent. Synthesized FIC5.9 is indicated with a 
red line and SI-labeled FIC5.9 peptide is indicated with a blue line. (B) Quantification of FIC5.9 
synthesized by coagulation reactivation. The relative intensity of FIC5.9 was calculated by comparing with 
the intensity of the internal standard (SI-FIC5.9). 
 
FIGURE 3. Cleavage site mapping of thrombin, plasmin and neutrophil elastase in FIC5.9 and surrounding 
regions. Cleavage sites are indicated with scissors, depending on the number of peptides identified by 
LC-MS/MS analysis. Identified peptide sequence information is shown in Supplementary Table 1. 
 
TABLE Identified peptides cleaved by thrombin, plasmin and neutrophil elastase in FIC5.9 and 
surrounding regions by LC-MS/MS analysis. (O) indicates “oxidized”, and duplication is eliminated. 
 
FIGURE 4. Analysis of synthesis and time course of FIC5.9 in plain and silica-coated tubes. The relative 
amount of FIC5.9 was measured by FIC5.9 ELISA. Statistical analysis was performed as described in the 
Materials and Methods. 
 
FIGURE 5. Analysis of synthesis and time course of FIC5.9 with thrombin spiked/inhibited (A), plasmin 
spiked/inhibited (B), or neutrophil elastase inhibited (C) blood collection tubes. The relative amount of 
FIC5.9 was measured by FIC5.9 ELISA. Statistical comparison of silica-coated tube vs. enzyme-spiked 
tube (*), or inhibitor spiked tube (†) was performed as described in the Materials and Methods. 
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 TABLE 
 
Identified peptides cleaved by thrombin, plasmin and neutrophil elastase in FIC5.9 and surrounding 
regions by LC-MS/MS analysis. 
Enzyme Confirmed sequences 
Thrombin 
(7 Peptides) 
574- GKSSSYSKQFTSSTSYNRGDSTFESKSYKMADEA -604 
574- GKSSSYSKQFTSSTSYNRGDSTFESKSYKM -603 
576- SSSYSKQFTSSTSYNRGDSTFESKSYKMA -604 
576- SSSYSKQFTSSTSYNRGDSTFESKSYKM -603 
576- SSSYSKQFTSSTSYNRGDSTFESKS -600 
576- SSSYSKQFTSSTSYNRGDSTFESK -599 
576- SSSYSKQFTSSTSYNRGDSTFES -598 
Plasmin 
(26 Peptides) 
528- TFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGK -575 
528- TFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRG -574 
528- TFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSR -573 
528- TFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPS -572 
540- FVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGK -575 
541- VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGK -575 
548- GSESGIFTNTKESSSHHPGIAEFPSRGK -575 
548- GSESGIFTNTKESSSHHPGIAEFPSRGKSSSYS -580 
559- ESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSK -582 
559- ESRGSESGIFTNTKESSSHHPGIAEFPSRGK -575 
559- ESRGSESGIFTNTKESSSHHPGIAEFPSRG -574 
559- ESSSHHPGIAEFPSRGKSSSYS -580 
576- SSSYSKQFTSSTSYNRGDSTFESKSYK -602 
576- SSSYSKQFTSSTSYNRGDSTFESKS -600 
576- SSSYSKQFTSSTSYNRGDSTFESK -599 
576- SSSYSKQFTSSTSYNRGDSTFES -598 
576- SSSYSKQFTSSTSYNRGDST -595 
576- SSSYSKQFTSSTSYNRG -592 
576- SSSYSKQFTSSTSYN -590 
576- SSSYSKQFTSSTSY -589 
576- SSSYSKQFTSSTS -588 
582- QFTSSTSYNRGDSTFESKSYK -602 
582- QFTSSTSYNRGDSTFESKS -600 
603- MADEAGSEADHEGTHSTKRGHAK -625 
603- MADEAGSEADHEGTHSTKRGHA -624 
 603- MADEAGSEADHEGTHSTK -620 
Neutrophil 
Elastase 
(39 peptides) 
557- NTKESSSHHPGIAEFPSRGKSS -577 
557- NTKESSSHHPGIAEFPSRGKS -576 
557- NTKESSSHHPGIAEFPSRGK -575 
558- TKESSHHPGIAEFPS -572 
561- SSHHPGIAEFPSRGKS -576 
562- SHHPGIAEFPSRG -574 
562- SHHPGIAEFPSR -573 
568- AEFPSRGKSSSYSKQFT -584 
569- EFPSRGKSSSYSKQFT -584 
585- SSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629 
585- SSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTK -620 
585- SSTSYNRGDSTFESKSYKMA -604 
585- SSTSYNRGDSTFESKSYKM -603 
585- TSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629 
587- TSYNRGDSTFESKSYKMA -604 
587- TSYNRGDSTFESKSYKM -603 
588- SYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629 
588- SYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629(O) 
588- SYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAK -625 
588- SYNRGDSTFESKSYKMADEAGSEADHEGTHSTK -620 
588- SYNRGDSTFESKSYKMADEAGSEADHEGTH -617 
588- SYNRGDSTFESKSYKMADEA -607 
588- SYNRGDSTFESKSYKMA -604 
588- SYNRGDSTFESKSYKM -603 
588- SYNRGDSTFESKSYK -602 
596- FESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629 
596- FESKSYKMADEAGSEADHEGTHSTKRGHAK -625 
597- ESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629 
599- KSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629 
599- KSYKMADEAGSEADHEGTHSTKRGHAKSRPV -629(O) 
599- KSYKMADEAGSEADHEGTHSTKRGHAKSR -627 
599- KSYKMADEAGSEADHEGTHSTK -620 
599- KSYKMADEAGSEADHEGTHST -619 
599- KSYKMADEAGSEADHEGT -616 
601- YKMADEAGSEADHEGTHSTKRGHAKSRPV -629 
601- YKMADEAGSEADHEGTHSTKRGHAKSRPV -629(O) 
 601- YKMADEAGSEADHEGTHSTKRGHAKSRP -628 
601- YKMADEAGSEADHEGTHSTKRGHAK -625 
603- ADEAGSEADHEGTHSTKRGHAKSRPV -629 
None N.D. 
(O) indicates “oxidized”, and duplication is eliminated. 
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